New Jersey-based MonoSol Rx, the developer of PharmFilm drug delivery technology, has entered into a development and commercialization partnership with Iowa-based KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular disease, according to FierceDrugDelivery.
The companies will co-develop and commercialize KP106, KemPharm's prodrug for the treatment of ADHD utilizing MonoSol Rx's PharmFilm delivery platform. MonoSol Rx will have a significant financial stake in KP106, will be the exclusive manufacturer and be eligible for development milestone payments.
The drug development will combine MonoSol Rx's patent-protected pharmaceutical film technology with KemPharm's unique ADHD compound to provide improved compliance, safety and tolerability profiles to ADHD sufferers.
Phase I human clinical trial results demonstrated pharmacokinetics that predict a superior safety profile for KP106 as compared to Vyvanse, a currently marketed amphetamine stimulant for ADHD. In addition, preclinical studies suggest that the prodrug properties of KP106 may offer unique abuse deterrent properties as compared with current amphetamine-based treatments for ADHD.
A. Mark Schobel, president and CEO of MonoSol Rx, stated, "We are pleased to announce our partnership with KemPharm, and the opportunity to develop the first-ever ADHD drug delivered using PharmFilm…Our dosage form, in conjunction with KemPharm's KP106, has the potential to offer a safer, abuse-resistant and more effective treatment option for ADHD, which is particularly important given the concerns of patients, parents and caregivers regarding the risks associated with currently marketed ADHD drugs."